<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Naxitamab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Naxitamab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Naxitamab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="130244" href="/d/html/130244.html" rel="external">see "Naxitamab: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="130308" href="/d/html/130308.html" rel="external">see "Naxitamab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F55150211"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Naxitamab can cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor. Infusion reactions of any grade occurred in 94 to 100% of patients. Severe infusion reactions occurred in 32 to 68%, and serious infusion reactions occurred in 4 to 18% of patients in naxitamab clinical studies. Premedicate prior to each naxitamab infusion as recommended, and monitor patients for at least 2 hours following completion of each infusion. Reduce the rate, interrupt infusion, or permanently discontinue naxitamab based on severity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Naxitamab can cause severe neurotoxicity, including severe neuropathic pain, transverse myelitis, and reversible posterior leukoencephalopathy syndrome (RPLS). Pain of any grade occurred in 94 to 100% of patients of patients in naxitamab clinical studies. Premedicate to treat neuropathic pain as recommended. Permanently discontinue naxitamab based on the adverse reaction and severity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55158059"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Danyelza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55150214"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-GD2;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F55184476"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note:</b> Administer premedications to reduce the risk of infusion-related reactions and nausea/vomiting (naxitamab is associated with nausea and vomiting); administer pain management prior to and during infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6fc7672-3ba1-4f98-9c9e-f6cd53c46ea2">Neuroblastoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma (high risk), relapsed or refractory: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>3 mg/kg/day (maximum: 150 mg/day per the manufacturer’s labeling) on days 1, 3, and 5 of each 4-week treatment cycle (in combination with sargramostim [GM-CSF]). <b>Note: </b>Treatment cycles are repeated every 4 weeks until complete or partial response, followed by 5 additional cycles (every 4 weeks). Subsequent cycles may be repeated every 8 weeks. Discontinue (naxitamab and GM-CSF) with disease progression or unacceptable toxicity. Refer to sargramostim monograph for GM-CSF dosing.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Premedication: </i>Administer an antihistamine, an H<sub>2</sub> antagonist, acetaminophen, and an antiemetic 30 minutes prior to each naxitamab infusion. In addition, administer an IV corticosteroid such as methylprednisolone 2 mg/kg (maximum: 80 mg/dose) or equivalent corticosteroid 30 minutes to 2 hours prior to the first naxitamab infusion. The systemic corticosteroid may be administered for subsequent infusions if a severe infusion reaction occurred with the previous infusion (or during the previous cycle).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pain management (prior to and during naxitamab infusion): </i></p>
<p style="text-indent:-2em;margin-left:8em;">Day –4 through Day 7: Administer a 12-day course of a prophylactic medication for neuropathic pain (eg, gabapentin); initiate 5 days prior to the first naxitamab infusion in each cycle.</p>
<p style="text-indent:-2em;margin-left:8em;">Prior to and during infusion: Administer oral opioids 45 to 60 minutes prior to initiation of each naxitamab infusion; additional IV opioids may be administered, as needed, for breakthrough pain during the infusion. If pain is not adequately controlled by opioids, may consider ketamine.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose: </i>If a naxitamab dose is missed, administer the missed dose the following week (by day 10 of the cycle). Administer sargramostim (GM-CSF) on the first day of the naxitamab infusion, and on the day before and on the day of the second and third infusion, respectively (for a total of 5 days of the 500 mcg/m<sup>2</sup>/day sargramostim dose [refer to Sargramostim monograph for details]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55184477"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F55184478"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F57498323"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2 </sup>experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status. If dose reduction for toxicity is recommended in the prescribing information, the dose should be increased back to the initial or previously tolerated dose only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).<b> Note:</b> According to the prescribing information, the maximum dose is 150 mg/day.</p></div>
<div class="block dot drugH1Div" id="F55184479"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Naxitamab Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Grade</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>NSAIDs = nonsteroidal anti-inflammatory drugs.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold naxitamab or interrupt infusion until recovery to ≤ grade 2, then resume infusion at 50% of prior infusion rate. If tolerated (no recurrence of symptoms), gradually increase infusion rate to rate prior to onset of symptoms. Permanently discontinue naxitamab if no response to medication intervention.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Infusion-related reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2: Therapy/infusion interruption indicated but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDS<sup>a</sup>, narcotics, IV fluids); prophylactic medications indicated for ≤24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Reduce naxitamab infusion rate to 50% of previous rate. Monitor closely until improvement to ≤ grade 1, then increase infusion rate gradually as tolerated to rate prior to the event.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3: Prolonged reaction (eg, not rapidly responsive to symptomatic therapy and/or brief infusion interruption); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Immediately interrupt naxitamab infusion. Monitor closely until recovery to ≤ grade 2, then resume infusion at 50% of the previous rate and increase infusion rate gradually as tolerated to rate prior to the event. Permanently discontinue naxitamab if no response to medical intervention.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4: Life-threatening consequences; urgent intervention indicated <b>or </b>grade 3 or 4 anaphylaxis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Ocular (neurologic disorders of the eye)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grades 2 to 4 resulting in decreased visual acuity or limiting activities of daily living</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold naxitamab until resolution. If resolved, resume naxitamab at 50% of the prior <b>dose</b>; if tolerated (no recurrence of symptoms), gradually increase naxitamab <b>dose</b> to the dose prior to onset of symptoms. Permanently discontinue naxitamab if not resolved within 2 weeks, or if toxicity recurs.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Subtotal or total vision loss</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pain</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 (unresponsive to maximum supportive measures)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">≥ Grade 2 motor neuropathy</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">≥ Grade 3 sensory neuropathy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reversible posterior leukoencephalopathy syndrome (RPLS)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transverse myelitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Urinary retention, prolonged</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Persistent despite opioid discontinuation</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other adverse reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold naxitamab until recovery to ≤ grade 2, then resume naxitamab at the same rate. Permanently discontinue naxitamab if not resolved to ≤ grade 2 within 2 weeks.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr></tbody></table></div>
<div class="block dop drugH1Div" id="F55175840"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130244" href="/d/html/130244.html" rel="external">see "Naxitamab: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer premedications to reduce the risk of infusion-related reactions and nausea/vomiting (naxitamab is associated with nausea and vomiting); administer pain management prior to and during infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6fc7672-3ba1-4f98-9c9e-f6cd53c46ea2">Neuroblastoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma (high-risk), relapsed or refractory:</b> Children and Adolescents: IV: 3 mg/kg/day (maximum dose: 150 mg/<b>day</b>) on days 1, 3, and 5 of each treatment cycle (in combination with sargramostim [GM-CSF]). Treatment cycles are repeated every 4 weeks until complete or partial response, followed by 5 additional cycles (every 4 weeks). Subsequent cycles may be repeated every 8 weeks. Discontinue for unacceptable toxicity or if patient experiences disease progression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication</i>: Administer an H<sub>1</sub> antagonist antihistamine, an H<sub>2</sub> antagonist antihistamine, acetaminophen, and an antiemetic 30 minutes prior to each naxitamab infusion. In addition, administer an IV corticosteroid such as methylprednisolone 2 mg/kg (maximum: 80 mg/dose) or equivalent 30 minutes to 2 hours prior to the first naxitamab infusion. For subsequent infusions, administer systemic corticosteroid if a severe infusion reaction occurred with the previous infusion (or during the previous cycle).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pain management (prior to and during naxitamab infusion)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Day −4 through Day 7: Administer a 12-day course of a prophylactic medication for neuropathic pain (eg, gabapentin); initiate 5 days (Day −4) prior to the first naxitamab infusion in each cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Prior to and during infusion: Administer oral opioids 45 to 60 minutes prior to initiation of each naxitamab infusion; additional IV opioids may be administered as needed for breakthrough pain during the infusion. If pain is not adequately controlled by opioids, may consider ketamine.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Children and Adolescents:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Naxitamab Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Grade</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Dosage modification</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold naxitamab or interrupt infusion until recovery to ≤ grade 2, then resume infusion at 50% of prior infusion rate. If tolerated (no recurrence of symptoms), gradually increase infusion rate to rate prior to onset of symptoms. Permanently discontinue naxitamab if no response to medical intervention.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Infusion-related reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Reduce naxitamab infusion rate to 50% of previous rate. Monitor closely until improvement to ≤ grade 1, then increase infusion rate gradually as tolerated to rate prior to the event.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Immediately interrupt naxitamab infusion. Monitor closely until recovery to ≤ grade 2, then resume infusion at 50% of the previous rate and increase infusion rate gradually as tolerated to rate prior to the event. Permanently discontinue naxitamab if no response to medical intervention.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4: Life-threatening consequences; urgent intervention indicated <b>or </b>grade 3 or 4 anaphylaxis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Ocular (neurologic disorders of the eye)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2 to 4 resulting in decreased visual acuity or limiting activities of daily living</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold naxitamab until resolution. If resolved, resume naxitamab at 50% of the prior <b>dose</b>; if tolerated (no recurrence of symptoms), gradually increase naxitamab <b>dose</b> to the dose prior to onset of symptoms. Permanently discontinue naxitamab if not resolved within 2 weeks, or if toxicity recurs.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Subtotal or total vision loss</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Pain</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 (unresponsive to maximum supportive measures)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Motor neuropathy ≥ Grade 2</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Sensory neuropathy ≥ Grade 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Reversible posterior leukoencephalopathy syndrome (RPLS)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Transverse myelitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Urinary retention, prolonged</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Persistent despite opioid discontinuation</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Other adverse reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold naxitamab until recovery to ≤ grade 2, then resume naxitamab at the same rate. Permanently discontinue naxitamab if not resolved to ≤ grade 2 within 2 weeks.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue naxitamab.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F55175908"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F55175909"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55646498"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bone marrow suppression, including <b>decreased hemoglobin</b>, <b>decreased neutrophils</b>, <b>decreased platelet count</b>, and <b>lymphocytopenia</b>, occurred commonly with naxitamab treatment, including severe grade 3 and 4 events.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity/infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Naxitamab commonly causes <b>infusion related reactions </b>and reactions may be severe. Infusion-related reactions included <b>anaphylaxis</b>, <b>hypotension</b>, <b>bronchospasm</b>, stridor, and cardiac arrest. In 2 small clinical trials, infusion reactions of any grade occurred in 94% to 100% of patients; grade 3 and 4 reactions occurred in 32% to 68%, and serious reactions occurred in 4% to 18% of patients. A majority of patients required a reduction in infusion rate and/or interruption of infusion for at least 1 infusion reaction; permanent discontinuation may also be required depending on severity of reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; usually within 24 hours of completion of infusion, with most occurring within 30 minutes of initiation of the infusion; reactions were most frequent during the first infusion in each cycle.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Infusion rate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension </b>was commonly observed, frequently as grade 3 and 4 events. Depending on severity, hypertension may warrant withholding or interrupting the infusion, decreasing infusion rate, or permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; while most cases occurred on the day of infusion, some occurred up to 9 days following infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Uncontrolled hypertension (do not initiate in these patients)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Naxitamab may cause <b>severe neurotoxicity</b>, including severe <b>neuralgia </b>(or neuropathic pain), <b>transverse myelitis</b> and <b>reversible posterior leukoencephalopathy syndrome</b> (RPLS). Mild and moderate <b>peripheral neuropathy</b>, which included peripheral sensory, motor neuropathy, paresthesia, and neuralgia, were also commonly reported. In addition, neurological ophthalmic disorders, including <b>anisocoria</b>, <b>blurred vision</b>, <b>accommodation disturbance</b>, <b>mydriasis</b>, <b>visual impairment</b>, and <b>photophobia,</b> were commonly observed, with some having a prolonged duration. Neurotoxicities, depending on severity, may warrant infusion interruptions or permanent discontinuations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied</p>
<p style="text-indent:-2em;margin-left:6em;">Neuropathy: Most cases began on the day of infusion and lasted a median of ~6 days (range: 0 to 22 days).</p>
<p style="text-indent:-2em;margin-left:6em;">Neurological eye disorders: Onset unknown; events lasted a median of 1 to 17 days (range: 0 to 84 days).</p>
<p style="text-indent:-2em;margin-left:6em;">RPLS: Reported cases in clinical trials occurred 2 and 7 days following completion of the first naxitamab cycle.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain</b> (of any grade), including abdominal, bone, neck, and extremity pain, occurred in 94% to 100% of patients. Many of the reported cases were severe pain (grade 3 and 4 events). Neuropathic pain also occurs with therapy. Medications for pain management (opioids and an agent for neuropathic pain) are recommended prior to and during infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; pain (eg, abdominal, bone, neck, and extremity pain) usually began during the infusion and typically lasted a median of &lt;1 day (range: &lt;1 day to 62 days).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Urinary retention</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary retention</b>, including some cases persisting after discontinuation of opioids, have been observed. Permanent discontinuation may be required for persistent urinary retention.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Onset was on the day of infusion for all the cases during clinical trials, with a duration of up to 24 days.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55159638"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, hypertension, hypotension, sinus tachycardia, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, erythema of skin, hyperhidrosis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum calcium, decreased serum glucose, decreased serum magnesium, decreased serum phosphate, decreased serum potassium, decreased serum sodium, increased serum glucose, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, decreased appetite, diarrhea, nausea, viral gastrointestinal infection, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, decreased hemoglobin, decreased neutrophils, decreased platelet count, lymphocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction, localized edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, fatigue, headache, impaired consciousness, irritability, lethargy, pain, peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, anisocoria, blurred vision, mydriasis, photophobia, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Abnormal breath sounds, cough, nasal infection (viral), oropharyngeal pain, rhinorrhea, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, infusion related reaction (including severe infusion related reactions)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, shallow respiration</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system<b>: </b>Neuralgia (severe), reversible posterior leukoencephalopathy syndrome, severe neurotoxicity, transverse myelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, respiratory depression, stridor</p></div>
<div class="block coi drugH1Div" id="F55150217"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of severe hypersensitivity to naxitamab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55184468"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B virus screening: The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block foc drugH1Div" id="F55158060"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Danyelza: Naxitamab-gqgk 4 mg/mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F55158058"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55195463"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Danyelza Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/10 mL (per mL): $2,770.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F55184480"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Naxitamab may be associated with a moderate emetic potential; administer an antiemetic prior to each infusion. Administer in a setting where cardiopulmonary resuscitation medication and equipment is available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse the first infusion (day 1, cycle 1) over 60 minutes. Administer over 30 to 60 minutes as tolerated for subsequent infusions. Do not administer as an IV push or bolus. Observe patients for a minimum of 2 hours following each infusion. Premedication and pain management prior to infusions are required; refer to "Dosing: Adult."</p></div>
<div class="block admp drugH1Div" id="F55176318"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Naxitamab may be associated with a moderate emetic potential; administer an antiemetic, prior to each infusion. Administer an H<sub>1</sub> antagonist antihistamine , an H<sub>2</sub> antagonist antihistamine, and acetaminophen 30 minutes prior to each naxitamab infusion. Administer oral opioids 45 to 60 minutes prior to initiation of each naxitamab infusion; additional IV opioids may be administered as needed for breakthrough pain during the infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Infuse the first infusion (day 1, cycle 1) over 60 minutes. For subsequent infusions, administer over 30 to 60 minutes as tolerated. Do not administer as an IV push or bolus. Observe patients for a minimum of 2 hours following each infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose: </i>If a naxitamab dose is missed, administer the missed dose the following week (by day 10 of the cycle). Administer sargramostim (GM-CSF) on the first day of the naxitamab infusion, and on the day before and on the day of the second and third infusion, respectively (for a total of 5 days of the 500 mcg/m<sup>2</sup>/day sargramostim dose [refer to sargramostim monograph for details]).</p></div>
<div class="block use drugH1Div" id="F55150216"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Neuroblastoma, high risk, relapsed or refractory:</b> Treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow (in combination with granulocyte-macrophage colony-stimulating factor [GM-CSF]), in pediatric patients ≥1 year of age and adults who have demonstrated a partial response, minor response, or stable disease to prior therapy.</p></div>
<div class="block mst drugH1Div" id="F55184463"><span class="drugH1">Medication Safety Issues</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sound-alike/look-alike issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Naxitamab may be confused with dinutuximab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>High alert medication:</b></p>
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
<div class="block cyt drugH1Div" id="F55194899"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55194896"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55184466"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during therapy and for 2 months after the last naxitamab dose.</p></div>
<div class="block pri drugH1Div" id="F55184465"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Naxitamab is a humanized monoclonal antibody (IgG1). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, in utero exposure to naxitamab may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F55184467"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if naxitamab is present in breast milk. However, naxitamab is a humanized monoclonal antibody (IgG<sub>1</sub>) and human IgG is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 2 months after the last naxitamab dose.</p></div>
<div class="block mop drugH1Div" id="F55184483"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hepatitis B virus screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning systemic anticancer therapy (ASCO [Hwang 2020]). Evaluate pregnancy status prior to use in patients who may become pregnant. Monitor closely for signs/symptoms of infusion reactions (during and for at least 2 hours after infusion completion). Monitor BP during infusion and at least daily on days 1 to 8 of each cycle; monitor for hypertensive complications. Monitor for signs/symptoms of pain, transverse myelitis, reversible leukoencephalopathy syndrome, peripheral neuropathy, urinary retention, and ocular symptoms.</p></div>
<div class="block pha drugH1Div" id="F55184472"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Naxitamab binds to the glycolipid disialoganglioside (GD2), which is highly expressed in neuroblastoma, and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. By binding to cell surface GD2, naxitamab induces cell lysis (of GD2-expressing cells) through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p></div>
<div class="block phk drugH1Div" id="F55184473"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized into small peptides by catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 8.2 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216304"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Danyelza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Danyelza.2020.11">
<a name="Danyelza.2020.11"></a>Danyelza (naxitamab) [prescribing information]. New York, NY: Y-mAbs Therapeutics Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naxitamab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naxitamab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naxitamab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/naxitamab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 130243 Version 40.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
